Neogen Corporation

Glucotrack, Bausch Health, and Corcept Therapeutics were among Thursday's top biotech gainers, driven by pipeline progress and strong financial results. Glucotrack's subsidiary Lokahi Therapeutics advanced development of LT-100, a non-narcotic therapy derived from honeybee venom, with plans to begin clinical evaluation of a simplified single-injection method as early as the fourth quarter of 2026, sending shares up 173.68% to $0.78. Bausch Health raised its full-year 2026 revenue outlook to between $10.790 billion and $11.040 billion after reporting second-quarter consolidated revenue of $2.85 billion, a 13% increase, and its stock rose 28.85% to $6.03. Corcept Therapeutics posted second-quarter net income of $43.0 million on revenue of $256.1 million, including $208.6 million from Korlym and its authorized generic and $47.6 million from newly launched Lifyorli, and lifted its 2026 revenue forecast to $1.1 billion to $1.2 billion, pushing shares up 27.29% to $118.32. Nuwellis surged 135.45% to $4.45 after a study on its Aquadex therapy was accepted by a peer-reviewed journal, while Neogen touched a 52-week high of $11.56 and closed up 22.26% at $11.53 following its fiscal 2026 results and fiscal 2027 guidance.

Neogen reported fiscal fourth-quarter revenue of $225.3 million, with core revenue growth accelerating to 4.3%, its highest rate of fiscal 2026. Food safety revenue totaled $166.8 million and grew 5.8% on a core basis, while adjusted EBITDA rose 12% to $45.4 million. For fiscal 2027, the company forecast revenue of $880 million to $885 million and adjusted EBITDA of $180 million to $182 million, while planning to increase R&D spending by about 50% and invest $25 million in transformation initiatives. Neogen also repaid $20 million of its term loan and expects to use approximately $140 million from the planned Genomics business sale to repay debt and fund investments.

The global animal genetics market is projected to grow from USD 7.32 billion in 2025 to USD 13.90 billion by 2035, at a compound annual growth rate of 6.62 percent, according to a new report by SNS Insider. The genomic and genetic testing segment held the largest share at 48.2 percent in 2025 and is expected to grow at a CAGR of 7.3 percent, while the cattle segment accounted for about 45.5 percent of the market. North America led with a 37.5 percent share in 2025, and the Asia Pacific region is forecast to be the fastest-growing market at a CAGR of 8.4 percent. Key companies include Genus plc, Neogen Corporation, URUS Group, Zoetis Inc., and EW Group.

Neogen Corporation shares have surged 101.1% over the past year, sharply outperforming its industry's 30.4% decline and the S&P 500's 22.5% gain. The rally has been driven by strength in the Food Safety segment, where third-quarter fiscal 2026 revenues reached 157.6 million dollars with core revenue growth of 4%, supported by indicator testing, culture media, and pathogen test kits. The company also raised its full-year fiscal 2026 revenue guidance to a range of 857 million to 860 million dollars, up from 845 million to 855 million dollars. Recent product launches, including the Neogen MPNTray water testing system and the Listeria Right Now assay, along with progress integrating the former 3M Food Safety business, have bolstered investor confidence. However, Neogen faces headwinds from input cost inflation, global logistics disruptions, and freight cost increases of 1.5 million dollars per quarter, while carrying 793 million dollars in total outstanding debt against 159.9 million dollars in cash.